MARKET

ABIO

ABIO

Arca Biopharma Inc
NASDAQ
3.230
-0.020
-0.62%
After Hours: 3.180 -0.05 -1.55% 16:41 04/12 EDT
OPEN
3.290
PREV CLOSE
3.250
HIGH
3.310
LOW
3.152
VOLUME
354.13K
TURNOVER
0
52 WEEK HIGH
3.880
52 WEEK LOW
1.560
MARKET CAP
46.84M
P/E (TTM)
-8.7203
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ABIO last week (0401-0405)?
Weekly Report · 5d ago
ARCA biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024
Benzinga · 04/05 20:17
ADAGE CAPITAL MANAGEMENT, L.P. REPORTS 8.28% STAKE IN ARCA BIOPHARMA AS OF APRIL 3- SEC FILING
Reuters · 04/05 20:16
ARCA Biopharma stock drops on CEO departure
ARCA Biopharma shares down about 7% premarket after company and CEO Michael Bristow mutually agreed to conclude Bristow’s employment and service as a director. The Board appointed Thomas Keuer to serve as ARCA's President and principal executive officer. ARCA biopharma stock drops on CEO departure.
Seeking Alpha · 04/05 13:06
Altice USA, Genfit, Brooge Energy among premarket losers' pack
On the Move: Altice USA, Genfit, Brooge Energy among premarket losers' pack. HWH International, ARCA biopharma, ZCMD, HWH among the biggest morning stock movers. ATUS, GNFT, BROG and HWH are among the morning's biggest losers.
Seeking Alpha · 04/05 12:29
ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed merger of ARCA biopharma, Inc. And Oruka Therapeutics. KSF is seeking to determine whether the merger is fair to ARCA shareholders.
Barchart · 04/05 12:27
Arca Biopharma Announces Executive Leadership Transition
TipRanks · 04/04 20:43
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
More
About ABIO
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Webull offers Arca Biopharma Inc stock information, including NASDAQ: ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.